161 related articles for article (PubMed ID: 22606272)
21. Estrogen receptor α (ERα) status evaluation using RNAscope in situ hybridization: a reliable and complementary method for IHC in breast cancer tissues.
Yu X; Guo S; Song W; Xiang T; Yang C; Tao K; Zhou L; Cao Y; Liu S
Hum Pathol; 2017 Mar; 61():121-129. PubMed ID: 27993577
[TBL] [Abstract][Full Text] [Related]
22. BCAR4 induces antioestrogen resistance but sensitises breast cancer to lapatinib.
Godinho MF; Wulfkuhle JD; Look MP; Sieuwerts AM; Sleijfer S; Foekens JA; Petricoin EF; Dorssers LC; van Agthoven T
Br J Cancer; 2012 Sep; 107(6):947-55. PubMed ID: 22892392
[TBL] [Abstract][Full Text] [Related]
23. The prognostic and predictive value of ESR1 fusion gene transcripts in primary breast cancer.
Vitale SR; Ruigrok-Ritstier K; Timmermans AM; Foekens R; Trapman-Jansen AMAC; Beaufort CM; Vigneri P; Sleijfer S; Martens JWM; Sieuwerts AM; Jansen MPHM
BMC Cancer; 2022 Feb; 22(1):165. PubMed ID: 35151276
[TBL] [Abstract][Full Text] [Related]
24. Quantitative profiles of the mRNAs of ER-alpha and its novel variant ER-alpha36 in breast cancers and matched normal tissues.
Zheng Y; Zhang J; Xu ZZ; Sheng JM; Zhang XC; Wang HH; Teng XD; Liu XJ; Cao J; Teng LS
J Zhejiang Univ Sci B; 2010 Feb; 11(2):144-50. PubMed ID: 20104649
[TBL] [Abstract][Full Text] [Related]
25. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
[TBL] [Abstract][Full Text] [Related]
26. Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness-a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer.
Madeira M; Mattar A; Logullo AF; Soares FA; Gebrim LH
BMC Cancer; 2013 Sep; 13():425. PubMed ID: 24047421
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of BrightGen HR RT-qDx assay to detect nuclear receptors mRNA overexpression in FFPE breast cancer tissue samples for selection of tamoxifen therapy.
Wang HY; Park S; Kim S; Ahn S; Lee D; Kim S; Jung D; Park KH; Lee H
Int J Clin Exp Pathol; 2014; 7(9):5792-800. PubMed ID: 25337220
[TBL] [Abstract][Full Text] [Related]
28. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy.
Kuukasjärvi T; Kononen J; Helin H; Holli K; Isola J
J Clin Oncol; 1996 Sep; 14(9):2584-9. PubMed ID: 8823339
[TBL] [Abstract][Full Text] [Related]
29. ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6.
Filipits M; Rudas M; Singer CF; Fitzal F; Bago-Horvath Z; Greil R; Balic M; Lax SF; Halper S; Hulla W; Wu NC; Liu X; Weidler J; Bates M; Hlauschek D; Gnant M; Dubsky P
ESMO Open; 2021 Aug; 6(4):100228. PubMed ID: 34371382
[TBL] [Abstract][Full Text] [Related]
30. TSC22D1 and PSAP predict clinical outcome of tamoxifen treatment in patients with recurrent breast cancer.
Meijer D; Jansen MP; Look MP; Ruigrok-Ritstier K; van Staveren IL; Sieuwerts AM; van Agthoven T; Foekens JA; Dorssers LC; Berns EM
Breast Cancer Res Treat; 2009 Jan; 113(2):253-60. PubMed ID: 18299979
[TBL] [Abstract][Full Text] [Related]
31. Measuring IGF-1, ER-α and EGFR expression can predict tamoxifen-resistance in ER-positive breast cancer.
Chong K; Subramanian A; Sharma A; Mokbel K
Anticancer Res; 2011 Jan; 31(1):23-32. PubMed ID: 21273576
[TBL] [Abstract][Full Text] [Related]
32. Estrogen receptor 1 mRNA is a prognostic factor in ovarian carcinoma: determination by kinetic PCR in formalin-fixed paraffin-embedded tissue.
Darb-Esfahani S; Wirtz RM; Sinn BV; Budczies J; Noske A; Weichert W; Faggad A; Scharff S; Sehouli J; Oskay-Ozcelik G; Zamagni C; De Iaco P; Martoni A; Dietel M; Denkert C
Endocr Relat Cancer; 2009 Dec; 16(4):1229-39. PubMed ID: 19675076
[TBL] [Abstract][Full Text] [Related]
33. Characterization of BCAR4, a novel oncogene causing endocrine resistance in human breast cancer cells.
Godinho M; Meijer D; Setyono-Han B; Dorssers LC; van Agthoven T
J Cell Physiol; 2011 Jul; 226(7):1741-9. PubMed ID: 21506106
[TBL] [Abstract][Full Text] [Related]
34. Clinical Relevance of Targeting the Gastrin-Releasing Peptide Receptor, Somatostatin Receptor 2, or Chemokine C-X-C Motif Receptor 4 in Breast Cancer for Imaging and Therapy.
Dalm SU; Sieuwerts AM; Look MP; Melis M; van Deurzen CH; Foekens JA; de Jong M; Martens JW
J Nucl Med; 2015 Oct; 56(10):1487-93. PubMed ID: 26251419
[TBL] [Abstract][Full Text] [Related]
35. RNA-based determination of ESR1 and HER2 expression and response to neoadjuvant chemotherapy.
Denkert C; Loibl S; Kronenwett R; Budczies J; von Törne C; Nekljudova V; Darb-Esfahani S; Solbach C; Sinn BV; Petry C; Müller BM; Hilfrich J; Altmann G; Staebler A; Roth C; Ataseven B; Kirchner T; Dietel M; Untch M; von Minckwitz G
Ann Oncol; 2013 Mar; 24(3):632-9. PubMed ID: 23131391
[TBL] [Abstract][Full Text] [Related]
36. Multimodal Assessment of Estrogen Receptor mRNA Profiles to Quantify Estrogen Pathway Activity in Breast Tumors.
Muthukaruppan A; Lasham A; Woad KJ; Black MA; Blenkiron C; Miller LD; Harris G; McCarthy N; Findlay MP; Shelling AN; Print CG
Clin Breast Cancer; 2017 Apr; 17(2):139-153. PubMed ID: 27756582
[TBL] [Abstract][Full Text] [Related]
37. The Role of ESR1 Gene Polymorphic Markers in the Development of Breast Cancer and Resistance to Tamoxifen Therapy.
Lukina SS; Burdennyy AM; Zavarykina TM; Riabchikov DA; Kazubskaya TP; Kruglova MP; Loginov VI
Bull Exp Biol Med; 2021 Jan; 170(3):350-355. PubMed ID: 33452979
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of ESR1 amplification and ESR1 PvuII, CYP2C19*2, UGT2B15*2 polymorphisms in breast cancer patients.
Markiewicz A; Wełnicka-Jaśkiewicz M; Skokowski J; Jaśkiewicz J; Szade J; Jassem J; Zaczek AJ
PLoS One; 2013; 8(8):e72219. PubMed ID: 23951298
[TBL] [Abstract][Full Text] [Related]
39. Impact of estrogen receptor α on the tamoxifen response and prognosis in luminal-A-like and luminal-B-like breast cancer.
Babyshkina N; Vtorushin S; Dronova T; Patalyak S; Slonimskaya E; Kzhyshkowska J; Cherdyntseva N; Choynzonov E
Clin Exp Med; 2019 Nov; 19(4):547-556. PubMed ID: 31562548
[TBL] [Abstract][Full Text] [Related]
40. The detection of ESR1/PGR/ERBB2 mRNA levels by RT-QPCR: a better approach for subtyping breast cancer and predicting prognosis.
Du X; Li XQ; Li L; Xu YY; Feng YM
Breast Cancer Res Treat; 2013 Feb; 138(1):59-67. PubMed ID: 23397283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
